Skip to content
Screener

Boston Scientific BSX Q2 2026 earnings

Reported July 29, 2026 · Before market open

Revenue$5.4BBeat by $67.0M
Adjusted EPS$0.86Beat by $0.03
Revenue estimate$5.4B
EPS estimate$0.84
“We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific's long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians.”
Mike Mahoney

Earnings data and commentary were extracted with AI from company filings and may contain errors. Verify important details in the company filing.

Next report

Oct 28, 2026 (In 3 weeks)
Revenue estimate$5.1B
EPS estimate$0.77

Financials

Q2 2026

Income statement

See full
Revenue$5.4B+7.5%
Gross profit$3.8B+12.4%
Operating income$1.2B+43.8%
Net income$907.0M+14.1%
EPS (diluted)$0.61+15.1%

Valuation & ratios

Valuation

as of 10/02/26
See full
Market cap$62.65B-56.1%
P/E17.1×-34.2×
P/S3×-4.4×

Profitability

See full
Gross margin69.9%+1.7pp
Operating margin19.8%+2.8pp
Net margin17.5%+4.0pp

Segments

By segment

See full
Cardiovascular$3.6B+8.3%
MedSurg$1.8B+5.9%

FAQ

When did Boston Scientific report Q2 2026 earnings?
Boston Scientific (BSX) reported Q2 2026 earnings on July 29, 2026 before market open.
What were Boston Scientific's Q2 2026 revenue and EPS?
Boston Scientific reported revenue of $5.4B and adjusted eps of $0.86 for Q2 2026.
Did Boston Scientific beat estimates in Q2 2026?
Revenue beat the consensus estimate of $5.4B by $67.0M. EPS beat the consensus estimate of $0.83 by $0.03.
How did Boston Scientific's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 7.5% from $5.1B a year earlier.
Where can I find Boston Scientific's Q2 2026 SEC filings?
You can read the 8-K earnings release (0000885725-26-000049) and the 10-Q periodic report (0000885725-26-000053) directly on SEC EDGAR. The filing index links above go to sec.gov.